Maravai LifeSciences (MRVI) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.87B and a free-cash-flow yield of -6.8%. Over the most recent reported fiscal year, revenue declined 28.3%. Nama's AI scorecard rates it Sell, 3.3 out of 10. On 12-month momentum it ranks in the leading band of its market.
AI scorecard
Sell · 3.3/10
Negative, at the mild end of Sell. As of Nov 20, 2026.
Momentum
Leading · +121.3% over 12 months ex. last
Top 20% of its market on the past year's steady rise.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-84.9%
How far the last close sits under the highest price of the past five years.
Market cap
$1.87B
Trailing P/E
—
Price / book
5.5
Price / sales
8.8
FCF yield
-6.8%
Dividend yield
—
Gross margin
39.1%
Operating margin
-25.6%
Net margin
-30.8%
Revenue growth (YoY)
-28.3%
Revenue growth (3-yr annual)
-40.5%
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
0.6
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
MRVI earnings
Next report: Feb 24, 2027 (Q4 2026, EPS estimate -$0.04).
Beat the EPS estimate in 4 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 4, 2026
-$0.03
-$0.06
+50.0%
$45.85M
Q2 2026
Aug 6, 2026
-$0.02
-$0.04
+50.0%
$51.44M
Q1 2026
May 7, 2026
$0.01
-$0.05
+120.0%
$65.84M
Q4 2025
Feb 25, 2026
-$0.04
-$0.07
+42.9%
$49.87M
MRVI analyst price target
Median target $9.50 from 7 analysts, ranging $8.00 – $12.00.
Nama's AI scorecard currently rates Maravai LifeSciences Sell (3.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does MRVI report earnings?
Maravai LifeSciences's next scheduled report is on Feb 24, 2027. Analysts expect EPS of -$0.04.
What is the MRVI price target?
The median analyst price target from 7 analysts is $9.50, with a range of $8.00 – $12.00.
Is MRVI Shariah compliant?
Nama's AAOIFI-style screen reads Maravai LifeSciences as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.